Novo Nordisk recruits new staff, lays off others as US R&D consolidated in Boston

In another sign that Boston continues to wear the U.S. biotech crown, Novo Nordisk will expand its R&D presence in the area at the expense of its Indianapolis and Seattle facilities.

The Danish drugmaker will bring 200 jobs to the greater Boston metro area, building on the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts to house the majority of the Big Pharma’s U.S.-based R&D activities.